MedPath

FDA Approves CRISPR-Based Gene Therapy Casgevy for Transfusion-Dependent Beta Thalassemia

• The FDA has approved Casgevy, a CRISPR-based gene therapy, for treating transfusion-dependent beta thalassemia, marking the second major U.S. approval for CRISPR technology. • Casgevy modifies patients' blood cells to increase hemoglobin production, reducing or eliminating the need for regular blood transfusions in individuals with the genetic disorder. • Developed by Vertex Pharmaceuticals and CRISPR Therapeutics, Casgevy is administered through stem cell transplantation at authorized treatment centers, with nine currently active in the U.S. • Common side effects include mouth sores, fever due to low white blood cell count, and decreased appetite, but the therapy offers a potentially curative option for this serious blood disorder.

The Food and Drug Administration (FDA) has approved Casgevy, a groundbreaking CRISPR-based gene therapy developed by Vertex Pharmaceuticals and CRISPR Therapeutics, for the treatment of transfusion-dependent beta thalassemia. This marks the second major regulatory approval in the U.S. for a CRISPR-based therapy and offers a potentially curative option for patients with this severe genetic blood disorder.
Casgevy utilizes CRISPR gene-editing technology to modify a patient's blood cells. The modified cells are then transplanted back into the patient's bone marrow, which triggers an increase in the production of hemoglobin, the protein in red blood cells that carries oxygen. Beta thalassemia is characterized by reduced or absent hemoglobin production, leading to severe anemia and a lifelong dependence on blood transfusions.

Clinical Impact and Administration

The approval of Casgevy offers a significant advancement in the treatment of transfusion-dependent beta thalassemia. Regular blood transfusions, while life-saving, can lead to iron overload and other complications. Casgevy aims to address the root cause of the disease by correcting the genetic defect responsible for reduced hemoglobin production.
Vertex Pharmaceuticals is establishing a network of independently operated, authorized treatment centers throughout the U.S. to administer Casgevy. As of the approval date, nine treatment centers are activated, with more expected to come online in the near future. The administration of Casgevy requires expertise in stem cell transplantation, ensuring that patients receive the therapy in a safe and effective manner.

CRISPR Technology and Future Prospects

CRISPR, short for "clustered regularly interspaced short palindromic repeats," is a revolutionary gene-editing tool that allows scientists to make precise changes to DNA. The discovery of CRISPR has transformed molecular life sciences and opened new avenues for treating genetic diseases. Emmanuelle Charpentier and Jennifer Doudna were awarded the Nobel Prize in 2020 for their groundbreaking work on CRISPR technology.
The approval of Casgevy for transfusion-dependent beta thalassemia follows the recent approval of the same therapy for sickle cell disease, further validating the potential of CRISPR-based therapies to address previously untreatable genetic conditions. The most common side effects observed during clinical trials included mouth sores, fever caused by low white blood cell count, and decreased appetite. These side effects are generally manageable and are associated with the stem cell transplantation process.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

CASGEVY Shows Durable Clinical Benefits in Sickle Cell Disease and Beta Thalassemia

Long-term data from clinical trials demonstrate the sustained benefits of CASGEVY™ in patients with severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).
In SCD, 93% of evaluable patients were free from vaso-occlusive crises (VOCs) for at least 12 consecutive months, with a mean VOC-free duration of 30.9 months.

FDA Approves PTC Therapeutics' Kebilidi, First Gene Therapy Dosed Directly into the Brain

The FDA has approved Kebilidi (eladocagene exuparvovec), a gene therapy by PTC Therapeutics, for aromatic L-amino acid decarboxylase (AADC) deficiency, a rare genetic disorder.
Kebilidi is the first gene therapy approved in the U.S. that involves direct administration into the brain, offering a novel approach to treating AADC deficiency.

PTC Therapeutics' Gene Therapy Kebilidi Receives FDA Approval for AADC Deficiency

The FDA has granted accelerated approval to PTC Therapeutics' Kebilidi, a gene therapy for Aromatic L-amino acid decarboxylase (AADC) deficiency, marking the first such therapy approved in the U.S.
Kebilidi delivers a functioning DDC gene directly into the brain, addressing the genetic defect underlying AADC deficiency, a severe neurological disorder affecting infants.

FDA Approves Kebilidi, First Gene Therapy Directly Administered to the Brain for AADC Deficiency

The FDA has granted accelerated approval to Kebilidi (eladocagene exuparvovec-tneq), a gene therapy for both children and adults with AADC deficiency, a rare genetic disorder.
Kebilidi, developed by PTC Therapeutics, is the first gene therapy approved in the U.S. that is directly administered to the brain via a stereotactic surgical procedure.

FDA Approves PTC Therapeutics' Kebilidi, First Direct-to-Brain Gene Therapy

The FDA has approved PTC Therapeutics' Kebilidi (eladocagene exuparvovec-tneq) for aromatic L-amino acid decarboxylase (AADC) deficiency, a rare genetic disorder.
Kebilidi is the first gene therapy approved by the FDA that is administered directly into the brain, specifically targeting the putamen region.

FDA Approves PTC Therapeutics' Kebilidi, First Gene Therapy for AADC Deficiency

The FDA has granted accelerated approval to PTC Therapeutics' Kebilidi (eladocagene exuparvovec-tneq) for treating AADC deficiency in patients aged 18 months and older.
Kebilidi is the first gene therapy administered directly to the brain to be approved in the United States for this rare genetic disorder.

FDA Approves Gene Therapies Casgevy and Lyfgenia for Sickle Cell Disease

The FDA has approved Casgevy (Vertex Pharmaceuticals) and Lyfgenia (Bluebird Bio) as novel gene therapies for sickle cell disease, offering potential long-term solutions.
Casgevy utilizes CRISPR/Cas9 technology to reactivate fetal hemoglobin production, while Lyfgenia employs a viral vector to introduce a functional hemoglobin gene.

CRISPR Technology Shows Promise Across Diverse Clinical Applications

CRISPR-Cas9 gene editing has achieved a significant milestone with FDA approval of Casgevy for sickle cell disease and transfusion-dependent beta thalassemia.
Clinical trials are underway for CRISPR-based therapies targeting urinary tract infections, hereditary transthyretin amyloidosis, hereditary angioedema, and cardiovascular diseases.

CRISPR Clinical Trials: A 2024 Update

The article provides an update on CRISPR-based therapies, highlighting the first-ever approval of a CRISPR-based medicine, Casgevy, for sickle cell disease and transfusion-dependent beta thalassemia. It discusses the progress, challenges, and future directions of CRISPR clinical trials across various diseases, including blood disorders, chronic bacterial infections, protein-folding diseases, inflammatory diseases, cancers, cardiovascular disease, HIV/AIDS, diabetes, and autoimmune diseases.

FDA Approves Krystal Biotech's Vyjuvek, a Topical Gene Therapy for Dystrophic Epidermolysis Bullosa

The FDA has approved Vyjuvek, Krystal Biotech's topical gene therapy, marking the first treatment of its kind for dystrophic epidermolysis bullosa.
Vyjuvek is approved for patients aged six months and older with either recessive or dominant forms of dystrophic epidermolysis bullosa.

Reference News

[1]
FDA Approves New CRISPR Gene-Editing Treatment
forbes.com · Jan 16, 2024

The FDA approved Casgevy, a CRISPR-based therapy by Vertex Pharmaceuticals and CRISPR Therapeutics, for treating transfu...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy